Where does Cellular Biomedicine Group HK Limited rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Cellular Biomedicine Group HK Limited ranks #28,367 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Cellular Biomedicine Group HK Limited hold?

Cellular Biomedicine Group HK Limited holds 9 US utility patents granted between 2021 and 2022, spanning 5 technology areas.

What is Cellular Biomedicine Group HK Limited's Innovation Score?

Cellular Biomedicine Group HK Limited has an Innovation Score of 34.7 out of 100 (49th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Cellular Biomedicine Group HK Limited's patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Cellular Biomedicine Group HK Limited.

What does claim depth mean for Cellular Biomedicine Group HK Limited's patents?

Cellular Biomedicine Group HK Limited's patents average 9.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Cellular Biomedicine Group HK Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Cellular Biomedicine Group HK Limited

Q: What technology areas does Cellular Biomedicine Group HK Limited focus on?

Cellular Biomedicine Group HK Limited's top technology area is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media) with 7 patents. Grants appear in 5 CPC subclasses total.

USPTO PatentsView assignee record - 9 granted patents across 5 technology areas, recorded in grant years 2021–2022. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Cellular ranks #28,367 of 49,997 tracked US assignees by granted-patent volume, with 9 patents across 5 technology areas.

#28,367
of 49,997 US assignees by volume: 49th percentile
by Innovation Score (34.7/100): 9.2
avg claims per patent

USPTO PatentsView assignee plate

Corpus R28367 · Foreign Corporation #28,367 · 9 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 9 grants
MID-PACK #28,367/49,997
PHOTO-FINISH CCA and B
CPC-NARROW C12N · 5 areas
INNOV-THIN 34.7/100
CLAIMS-PAR 9.2 claims/avg
TYPE-FRNCORP Foreign Corp
SPAN-YRS 2021–2022 · 2y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: CCA and B, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Cellular Biomedicine… · this assignee

35
3D Lighting… · lowest

7

What this shows Cellular's Innovation Score is 34.7/100 (49th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Cellular's grants concentrate

Cellular Biomedicine Group HK Limited is a focused PatentsView assignee: 5 CPC subclasses with 77.8% of grants classified under C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media). Peak complete grant year is 2022 (6 grants) versus a trough of 3 in 2021. By volume, Cellular sits between CCA and B, LLC and Center FOR Abrasives AND Refractories Research & Development C.A.R.R.D. GMBH.

Cellular's three-year grant acceleration

Cellular Biomedicine Group HK Limited shows 6 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

CCA and B

9
Cccc First Harbor…

9
CCS Contractor Eq…

9
Cellomics

9
Celon Pharma

9
Celyad

9
Cemedine

9
Center FOR Abrasi…

9
Cellular Biomedic… ◀

9

What this shows Cellular holds 9 patents at rank #28,338, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Cellular

By rank, the assignees closest to #28,338 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Cellular's primary technology class.

Cellular's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

35 49th percentile higher than 49% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2021–2022

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table

Cellular Biomedicine Group HK Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2021	3	33.3%
2022	6	66.7%

Which technologies does Cellular Biomedicine Group HK Limited patent most?

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 7

C07K - Peptides 7

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 7

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 6

A01N - Preservation OF Bodies OF Humans OR Animals OR Plants OR Parts Thereof ; Biocides, e.g. AS Disinfectants, AS Pesticides OR AS Herbicides ; Pest Repellants OR ATTRACTANTS; Plant Growth Regulators 1

Top 5 of 5 technology areas

Where it ranks

Overall rank by patents

#28,367

of 49,997 tracked assignees

Innovation Score

34.7 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Cellular Biomedicine Group HK Limited's patent record in context - here's where to go next.

Cellular Biomedicine Group HK Limited's lead technology class is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media), 77.8% of its portfolio - see every assignee active in that class. Explore C12N
Ranked #28,367 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Cellular Biomedicine Group HK Limited against CCA and B, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 34.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.